274. Osteogenesis Imperfecta Clinical trials / Disease details
Clinical trials : 91 / Drugs : 101 - (DrugBank : 20) / Drug target genes : 11 - Drug target pathways : 48
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04152551 (ClinicalTrials.gov) | November 2, 2019 | 18/10/2019 | Effects of Bisphosphonates on OI-Related Hearing Loss | Effects of Bisphosphonates on OI-Related Hearing Loss: A Pilot Study | Osteogenesis Imperfecta | Drug: Risedronate Oral Tablet | Hospital for Special Surgery, New York | The New York Community Trust;East River Medical Imaging;Northwell Health | Recruiting | 6 Years | 100 Years | All | 100 | Phase 4 | United States |